Skip to main content

The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis.

Publication ,  Journal Article
D'Souza, A; Magnus, BE; Myers, J; Dispenzieri, A; Flynn, KE
Published in: Amyloid
June 2020

We sought to evaluate how PROMIS patient-reported outcome (PRO) measures correlated with disease characteristics in systemic light chain (AL) amyloidosis patients at diagnosis. Newly diagnosed AL patients were recruited at two centres (N = 61). Patients completed the PROMIS Global Health v1.2, PROMIS-29 Profile v2.0 and Fatigue 8a v1.0. We assigned disease severity based on stage, presence of cardiac AL, and number of organs involved. We evaluated a) known groups validity by comparing PROMIS T-scores by disease severity, b) internal consistency using Cronbach's alpha and c) convergent/discriminant validity based on correlations across the domains and summary scores. Using receiver operating characteristic (ROC) curve analysis, NT-proBNP cut-off level corresponding to normal/mild vs moderate/severe PRO scores was determined. The median age was 68 (48-83) years with 58% males. Sixty-six percent had cardiac involvement and 25% had 3 or more organs involved with AL amyloidosis; 14% had stage 1, 28% stage 2, 36% stage 3 and 16% stage 4 disease. PROMIS measures had acceptable to excellent internal consistency and expected patterns of correlations. PROMIS Global Physical Health score was worse than the Global Mental Health Score at diagnosis; Physical function, fatigue and anxiety were the most impaired domains. PROMIS Global Health summary scores discriminated across AL amyloidosis stage and number of organs involved. Physical Function showed the strongest effects across known groups by stage, cardiac involvement and number of organs involved followed by Ability to Participate in Social Roles and Activities. A diagnostic NT-proBNP cut-off of 4200 pg/ml identified patients with moderate/severe PRO scores for these domains. Our results provide evidence for reliability and validity of select PROMIS short form measures in AL amyloidosis at diagnosis.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Amyloid

DOI

EISSN

1744-2818

Publication Date

June 2020

Volume

27

Issue

2

Start / End Page

111 / 118

Location

England

Related Subject Headings

  • Severity of Illness Index
  • Quality of Life
  • Patient Reported Outcome Measures
  • Middle Aged
  • Male
  • Immunoglobulin Light-chain Amyloidosis
  • Humans
  • Female
  • Fatigue
  • Biochemistry & Molecular Biology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
D’Souza, A., Magnus, B. E., Myers, J., Dispenzieri, A., & Flynn, K. E. (2020). The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis. Amyloid, 27(2), 111–118. https://doi.org/10.1080/13506129.2020.1713743
D’Souza, Anita, Brooke E. Magnus, Judith Myers, Angela Dispenzieri, and Kathryn E. Flynn. “The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis.Amyloid 27, no. 2 (June 2020): 111–18. https://doi.org/10.1080/13506129.2020.1713743.
D’Souza A, Magnus BE, Myers J, Dispenzieri A, Flynn KE. The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis. Amyloid. 2020 Jun;27(2):111–8.
D’Souza, Anita, et al. “The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis.Amyloid, vol. 27, no. 2, June 2020, pp. 111–18. Pubmed, doi:10.1080/13506129.2020.1713743.
D’Souza A, Magnus BE, Myers J, Dispenzieri A, Flynn KE. The use of PROMIS patient-reported outcomes (PROs) to inform light chain (AL) amyloid disease severity at diagnosis. Amyloid. 2020 Jun;27(2):111–118.

Published In

Amyloid

DOI

EISSN

1744-2818

Publication Date

June 2020

Volume

27

Issue

2

Start / End Page

111 / 118

Location

England

Related Subject Headings

  • Severity of Illness Index
  • Quality of Life
  • Patient Reported Outcome Measures
  • Middle Aged
  • Male
  • Immunoglobulin Light-chain Amyloidosis
  • Humans
  • Female
  • Fatigue
  • Biochemistry & Molecular Biology